Clinically significant molecular markers for urologic disease

Focus on bladder, kidney, and prostate cancer

Lance P. Walsh, Yair Lotan

Research output: Contribution to journalArticle

Abstract

The most important tools for making therapeutic decisions include stage and grade for bladder and kidney cancer, as well as PSA for prostate cancer. Unfortunately, all tumors of the same stage and grade do not behave the same, indicating the need for additional markers that can provide more accurate prognostic ability. The exponential increase in our understanding of the molecular mechanisms of disease during the past 2 decades has been aided by a large array of bladder, prostate, and kidney cancer biomarkers with potential diagnostic and prognostic value. This article reviews the molecular biomarkers that have shown to be clinically useful in the diagnosis and prognosis of urologic tumors. Ultimately, molecular markers may provide information that can be used to tailor the treatment of individual patients.

Original languageEnglish (US)
Pages (from-to)429-435
Number of pages7
JournalLaboratory Medicine
Volume37
Issue number7
DOIs
StatePublished - Jul 2006

Fingerprint

Urologic Diseases
Kidney Neoplasms
Urinary Bladder Neoplasms
Tumors
Prostatic Neoplasms
Aptitude
Biomarkers
Tumor Biomarkers
Neoplasms
Decision Making
Therapeutics

ASJC Scopus subject areas

  • Clinical Biochemistry
  • Pathology and Forensic Medicine

Cite this

Clinically significant molecular markers for urologic disease : Focus on bladder, kidney, and prostate cancer. / Walsh, Lance P.; Lotan, Yair.

In: Laboratory Medicine, Vol. 37, No. 7, 07.2006, p. 429-435.

Research output: Contribution to journalArticle

@article{447dce9fe0b54a06a46e1c543c3c603e,
title = "Clinically significant molecular markers for urologic disease: Focus on bladder, kidney, and prostate cancer",
abstract = "The most important tools for making therapeutic decisions include stage and grade for bladder and kidney cancer, as well as PSA for prostate cancer. Unfortunately, all tumors of the same stage and grade do not behave the same, indicating the need for additional markers that can provide more accurate prognostic ability. The exponential increase in our understanding of the molecular mechanisms of disease during the past 2 decades has been aided by a large array of bladder, prostate, and kidney cancer biomarkers with potential diagnostic and prognostic value. This article reviews the molecular biomarkers that have shown to be clinically useful in the diagnosis and prognosis of urologic tumors. Ultimately, molecular markers may provide information that can be used to tailor the treatment of individual patients.",
author = "Walsh, {Lance P.} and Yair Lotan",
year = "2006",
month = "7",
doi = "10.1309/3V02-UHC4-HVF4-MDQJ",
language = "English (US)",
volume = "37",
pages = "429--435",
journal = "Laboratory Medicine",
issn = "0007-5027",
publisher = "American Society of Clinical Pathologists",
number = "7",

}

TY - JOUR

T1 - Clinically significant molecular markers for urologic disease

T2 - Focus on bladder, kidney, and prostate cancer

AU - Walsh, Lance P.

AU - Lotan, Yair

PY - 2006/7

Y1 - 2006/7

N2 - The most important tools for making therapeutic decisions include stage and grade for bladder and kidney cancer, as well as PSA for prostate cancer. Unfortunately, all tumors of the same stage and grade do not behave the same, indicating the need for additional markers that can provide more accurate prognostic ability. The exponential increase in our understanding of the molecular mechanisms of disease during the past 2 decades has been aided by a large array of bladder, prostate, and kidney cancer biomarkers with potential diagnostic and prognostic value. This article reviews the molecular biomarkers that have shown to be clinically useful in the diagnosis and prognosis of urologic tumors. Ultimately, molecular markers may provide information that can be used to tailor the treatment of individual patients.

AB - The most important tools for making therapeutic decisions include stage and grade for bladder and kidney cancer, as well as PSA for prostate cancer. Unfortunately, all tumors of the same stage and grade do not behave the same, indicating the need for additional markers that can provide more accurate prognostic ability. The exponential increase in our understanding of the molecular mechanisms of disease during the past 2 decades has been aided by a large array of bladder, prostate, and kidney cancer biomarkers with potential diagnostic and prognostic value. This article reviews the molecular biomarkers that have shown to be clinically useful in the diagnosis and prognosis of urologic tumors. Ultimately, molecular markers may provide information that can be used to tailor the treatment of individual patients.

UR - http://www.scopus.com/inward/record.url?scp=33745768822&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33745768822&partnerID=8YFLogxK

U2 - 10.1309/3V02-UHC4-HVF4-MDQJ

DO - 10.1309/3V02-UHC4-HVF4-MDQJ

M3 - Article

VL - 37

SP - 429

EP - 435

JO - Laboratory Medicine

JF - Laboratory Medicine

SN - 0007-5027

IS - 7

ER -